Etoricoxib D3
| Product Name | Etoricoxib D3 |
|---|---|
| Alternate Names | Etoricoxib Stable Isotopes, Stable Isotopes of Etoricoxib |
| CAT No. | CS-O-15694 |
| CAS No. | 850896-71-8 |
| Category | Stable Isotopes |
| Stock | IN-Stock |
| Mol. Wt. | 361.86 g/mol |
| Mol. For. | C₁₈H₁₂D₃ClN₂O₂S |
| Hazardous | This is not a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Etoricoxib |
| Smileys | CC1=NC=C(C=C1)C2=C(C=C(C=N2)Cl)C3=CC=C(C=C3)S(=O)(=O)C |
| Canonical Smiles | CC1=NC=C(C=C1)C2=C(C=C(C=N2)Cl)C3=CC=C(C=C3)S(=O)(=O)C |
| InchIKey | MNJVRJDLRVPLFE-BMSJAHLVSA-N |
| Inchl | InChI=1S/C18H15ClN2O2S/c1-12-3-4-14(10-20-12)18-17(9-15(19)11-21-18)13-5-7-16(8-6-13)24(2,22)23/h3-11H,1-2H3/i2D3 |
| IUPAC | 5-chloro-2-(6-methylpyridin-3-yl)-3-[4-(trideuteriomethylsulfonyl)phenyl]pyridine |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Etoricoxib D3 is a deuterated derivative of Etoricoxib, a non-steroidal anti-inflammatory drug (NSAID) that is commonly used for the treatment of arthritis and other inflammatory conditions. The deuterium labeling in Etoricoxib D3 is used for pharmacokinetic and metabolic studies, and it does not affect the therapeutic effects of the drug.
Etoricoxib D3 works by inhibiting the cyclooxygenase-2 (COX-2) enzyme, which is responsible for the production of prostaglandins that cause inflammation, pain, and fever. By inhibiting COX-2, Etoricoxib D3 reduces inflammation and pain, and improves the mobility of joints affected by arthritis.
Etoricoxib D3 is available in tablet form for oral administration, with a recommended dosage of 60 mg or 90 mg once daily. It is important to follow the dosage instructions provided by a healthcare professional, as the dosage may vary depending on the condition being treated and the patient's medical history.
The chemical structure of Etoricoxib D3 is similar to that of other NSAIDs, with a sulfonamide group attached to a cyclooxygenase inhibitor. It has a molecular weight of 391.5 g/mol and a melting point of 234-238°C.
Like other NSAIDs, Etoricoxib D3 may cause side effects such as stomach upset, dizziness, and headache. It may also increase the risk of cardiovascular events such as heart attack and stroke, especially in patients with a history of cardiovascular disease. Therefore, it is important to use Etoricoxib D3 only under the supervision of a healthcare professional, and to report any unusual symptoms or side effects to them immediately.
Get an Instant Quote
Related Compounds
Etoricoxib D4 | Etoricoxib 13C6 | Etoricoxib 13CD3 |